MaaT Pharma

Equities

MAAT

FR0012634822

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 08:05:14 2024-04-26 am EDT			5-day change	1st Jan Change
9.06 ^EUR	0.00%		+3.90%	+29.80%

Apr. 15	MaaT Pharma: positive data in graft-versus-host disease	CF
Apr. 15	MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	CI

MaaT Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2023

September 26, 2023 at 12:00 pm EDT

MaaT Pharma SA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 1.38 million compared to EUR 0.494 million a year ago. Net loss was EUR 8.44 million compared to EUR 7.42 million a year ago.

Latest news about MaaT Pharma

MaaT Pharma: positive data in graft-versus-host disease	Apr. 15	CF
MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	Apr. 15	CI
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming to Improve Patients? Responses to Immunotherapies	Apr. 08	CI
MaaT Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
MaaT Pharma Names Chief Business Officer	Mar. 22	MT
Maat Pharma SA Appoint Jonathan Chriqui as Chief Business Officer	Mar. 21	CI
MaaT Pharma: Phase 2 trial recruitment completed	Mar. 05	CF
Maat Pharma Indicates Completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating Maat013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma	Mar. 05	CI
Transcript : MaaT Pharma SA - Special Call	Dec. 18
MaaT Pharma: positive results in blood cancers	Dec. 11	CF
MaaT Pharma to Receive EUR7 Million Government Funding for Blood Cancer Therapy Study	Dec. 01	MT
MaaT Pharma SA Announces Its Ongoing Phase 2B Trial, Called Phoebus, Aimed At Evaluating MaaT033 to Improve Overall Survival for Patients Receiving allo-HSCT2	Nov. 30	CI
Fragmented feeling?	Nov. 06
MaaT Pharma Begins Mid-stage Study for MaaT033 Capsule	Nov. 06	MT
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT	Nov. 06	CI
But where have the bears gone?	Nov. 03
MaaT Pharma’s Late-stage Study for MaaT013 Gets Data Safety Monitoring Board's Nod	23-10-26	MT
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-Versus-Host Disease with MaaT013	23-10-26	CI
MaaT Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Tech to the rescue	23-09-12
Correction: MaaT Pharma, Skyepharma Complete French Manufacturing Facility for Microbiome Ecosystem Therapies	23-09-12	MT
MaaT Pharma, Skyepharma Complete French Manufacturing Facility for Microbiome Ecosystem Therapies	23-09-12	MT
MaaT Pharma's Clinical-stage Capsule Receives Orphan Drug Designation in Europe	23-09-07	MT
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in AGvHD	23-07-26	CI
MaaT PharmaÂ Announces Management Changes	23-06-21	CI

Chart MaaT Pharma

Duration

Period

More charts

Company Profile

MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for MaaT Pharma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.06 EUR

Average target price

15.5 EUR

Spread / Average Target

+71.08%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MAAT PHARMA	+29.80%	112M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs